Zentiva Overview

  • Founded
  • 1993
Founded
  • Status
  • Public
  • Employees
  • 4,700
Employees
  • Stock Symbol
  • 1SKF401E
Stock Symbol
  • Investments
  • 6
  • Share Price
  • $39.78
  • (As of Wednesday Closing)

Zentiva General Information

Description

Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25 European markets. The company therapeutic areas inlcude Cardiovascular, Central nervous system, Gastrointestinal and metabolic disorders, Anti-inflammatory and pain, Ophthalmology, Anti-infectives, Urology, Respiratory, Blood disorders, and Oncology.

Contact Information

Website
www.zentiva.com
Formerly Known As
Leciva
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
XBRA
Primary Office
  • U kabelovny 529/16
  • Dolní Měcholupy
  • Prague, 102 00
  • Czech Republic
+420 267 000 000

Zentiva Timeline

2019202020212022
Financing RoundFinancing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zentiva Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$39.78 $34.51 $12.93 - $112.05 3.17

Zentiva Financials Summary

In Thousands,
USD
TTM 31-Dec-2015 FY 2015 31-Dec-2015 FY 2014 31-Dec-2014
Revenue 125,622 125,622 185,331
EBITDA 37,918 37,918 67,796
Net Income 19,452 19,452 53,052
Total Assets 149,351 149,351 191,232
Total Debt 0 0 23
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zentiva Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zentiva‘s full profile, request access.

Request a free trial

Zentiva Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25
Drug Discovery
Prague, Czech Republic
4,700 As of 2022
00000
00 0000-00-00
000000&0

0000000

t dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut al
0000 000000000
Cambridge, MA
0000 As of 0000
00.000
000000000 00.000

000000 0

etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zentiva Competitors (43)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA 0000 00.000 000000000 00.000
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
00000000 000000000 Corporation Henderson, NV 000 00000 000000 - 000 00000
000000000 00000000 Corporation Pasadena, CA 000 00.000 000000 - 000 00.000
00000000 000000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
You’re viewing 5 of 43 competitors. Get the full list »

Zentiva Patents

Zentiva Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-2592680-A8 Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof Pending 06-Mar-2020 0000000000
GB-2592680-A Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof Pending 06-Mar-2020 0000000000 0
EP-3811932-A1 Dosage form of apalutamide Pending 22-Oct-2019 0000000000 0
EP-3766484-B1 Solid pharmaceutical dosage form comprising valsartan and sacubitril Active 19-Jul-2019 0000000000
EP-3766484-A1 Solid pharmaceutical dosage form comprising valsartan and sacubitril Granted 19-Jul-2019 A61K9/1617 0
To view Zentiva’s complete patent history, request access »

Zentiva Executive Team (7)

Name Title Board Seat Contact Info
Nick Haggar Chief Executive Officer
Kenneth Lynard Chief Financial Officer
You’re viewing 2 of 7 executive team members. Get the full list »

Zentiva Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zentiva Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Zentiva‘s full profile, request access.

Request a free trial

Zentiva Investments & Acquisitions (6)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000000 29-May-2020 0000000000 000.00 Buildings and Property 0000 0000
00000000 0000 07-Apr-2020 0000000000 Pharmaceuticals 0000 0000
00000000 0000 31-May-2019 0000000000 Pharmaceuticals 0000 0000
0000 000000 01-Apr-2019 0000000000 Distributors/Wholesale 0000 0000
Sicomed 12-Oct-2005 Merger/Acquisition 00000 Pharmaceuticals
You’re viewing 5 of 6 investments and acquisitions. Get the full list »

Zentiva Subsidiaries (2)

Company Name Industry Location Founded
Labormed Alvogen Pharmaceuticals Bucharest, Romania 1991
00000000 000000 Pharmaceuticals Bucharest, Romania
To view Zentiva’s complete subsidiaries history, request access »

Zentiva Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 11-Aug-2003 0000000000 Completed
  • 2 buyers
To view Zentiva’s complete exits history, request access »